Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice.

Stoddart CA, Joshi P, Sloan B, Bare JC, Smith PC, Allaway GP, Wild CT, Martin DE.

PLoS One. 2007 Nov 28;2(11):e1251.

2.

In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat).

Adamson CS, Ablan SD, Boeras I, Goila-Gaur R, Soheilian F, Nagashima K, Li F, Salzwedel K, Sakalian M, Wild CT, Freed EO.

J Virol. 2006 Nov;80(22):10957-71. Epub 2006 Sep 6.

3.

Alkyl Amine Bevirimat Derivatives Are Potent and Broadly Active HIV-1 Maturation Inhibitors.

Urano E, Ablan SD, Mandt R, Pauly GT, Sigano DM, Schneider JP, Martin DE, Nitz TJ, Wild CT, Freed EO.

Antimicrob Agents Chemother. 2015 Oct 19;60(1):190-7. doi: 10.1128/AAC.02121-15.

4.

The prototype HIV-1 maturation inhibitor, bevirimat, binds to the CA-SP1 cleavage site in immature Gag particles.

Nguyen AT, Feasley CL, Jackson KW, Nitz TJ, Salzwedel K, Air GM, Sakalian M.

Retrovirology. 2011 Dec 7;8:101. doi: 10.1186/1742-4690-8-101.

5.

Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection.

Smith PF, Ogundele A, Forrest A, Wilton J, Salzwedel K, Doto J, Allaway GP, Martin DE.

Antimicrob Agents Chemother. 2007 Oct;51(10):3574-81. Epub 2007 Jul 16.

6.

Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457).

Adamson CS, Waki K, Ablan SD, Salzwedel K, Freed EO.

J Virol. 2009 May;83(10):4884-94. doi: 10.1128/JVI.02659-08. Epub 2009 Mar 11.

7.
8.

Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection.

Martin DE, Salzwedel K, Allaway GP.

Antivir Chem Chemother. 2008;19(3):107-13. Review.

PMID:
19024627
9.

Validation of the SCID-hu Thy/Liv mouse model with four classes of licensed antiretrovirals.

Stoddart CA, Bales CA, Bare JC, Chkhenkeli G, Galkina SA, Kinkade AN, Moreno ME, Rivera JM, Ronquillo RE, Sloan B, Black PL.

PLoS One. 2007 Aug 1;2(7):e655.

10.

Incorporation of Privileged Structures into Bevirimat Can Improve Activity against Wild-Type and Bevirimat-Resistant HIV-1.

Zhao Y, Gu Q, Morris-Natschke SL, Chen CH, Lee KH.

J Med Chem. 2016 Oct 13;59(19):9262-9268. Epub 2016 Sep 22.

11.

Mechanistic Studies and Modeling Reveal the Origin of Differential Inhibition of Gag Polymorphic Viruses by HIV-1 Maturation Inhibitors.

Lin Z, Cantone J, Lu H, Nowicka-Sans B, Protack T, Yuan T, Yang H, Liu Z, Drexler D, Regueiro-Ren A, Meanwell NA, Cockett M, Krystal M, Lataillade M, Dicker IB.

PLoS Pathog. 2016 Nov 28;12(11):e1005990. doi: 10.1371/journal.ppat.1005990. eCollection 2016 Nov.

12.

The capsid-spacer peptide 1 Gag processing intermediate is a dominant-negative inhibitor of HIV-1 maturation.

Checkley MA, Luttge BG, Soheilian F, Nagashima K, Freed EO.

Virology. 2010 Apr 25;400(1):137-44. doi: 10.1016/j.virol.2010.01.028. Epub 2010 Feb 20.

13.

HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat.

Fun A, van Maarseveen NM, Pokorná J, Maas RE, Schipper PJ, Konvalinka J, Nijhuis M.

Retrovirology. 2011 Aug 24;8:70. doi: 10.1186/1742-4690-8-70.

14.

Phenotypic susceptibility to bevirimat in isolates from HIV-1-infected patients without prior exposure to bevirimat.

Margot NA, Gibbs CS, Miller MD.

Antimicrob Agents Chemother. 2010 Jun;54(6):2345-53. doi: 10.1128/AAC.01784-09. Epub 2010 Mar 22.

16.

Identification and Characterization of BMS-955176, a Second-Generation HIV-1 Maturation Inhibitor with Improved Potency, Antiviral Spectrum, and Gag Polymorphic Coverage.

Nowicka-Sans B, Protack T, Lin Z, Li Z, Zhang S, Sun Y, Samanta H, Terry B, Liu Z, Chen Y, Sin N, Sit SY, Swidorski JJ, Chen J, Venables BL, Healy M, Meanwell NA, Cockett M, Hanumegowda U, Regueiro-Ren A, Krystal M, Dicker IB.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):3956-69. doi: 10.1128/AAC.02560-15. Print 2016 Jul.

17.

Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers.

Martin DE, Blum R, Doto J, Galbraith H, Ballow C.

Clin Pharmacokinet. 2007;46(7):589-98.

PMID:
17596104
18.

[Prediction of the efficacy of bevirimat used for the treatment of HIV infection in Russia].

Kazennova EV, Vasil'ev AV, Bobkova MR.

Vopr Virusol. 2010 May-Jun;55(3):37-41. Russian.

PMID:
20608080
19.

Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1 maturation inhibitor bevirimat.

Adamson CS, Sakalian M, Salzwedel K, Freed EO.

Retrovirology. 2010 Apr 20;7:36. doi: 10.1186/1742-4690-7-36.

20.

Determinants of activity of the HIV-1 maturation inhibitor PA-457.

Li F, Zoumplis D, Matallana C, Kilgore NR, Reddick M, Yunus AS, Adamson CS, Salzwedel K, Martin DE, Allaway GP, Freed EO, Wild CT.

Virology. 2006 Dec 5-20;356(1-2):217-24. Epub 2006 Aug 22.

Supplemental Content

Support Center